Pasithea Therapeutics (KTTAW) Projected to Post Earnings on Wednesday

Pasithea Therapeutics (NASDAQ:KTTAW) is projected to release its results before the market opens on Wednesday, February 25th. Analysts expect Pasithea Therapeutics to post earnings of ($0.18) per share for the quarter.

Pasithea Therapeutics Stock Down 12.4%

Pasithea Therapeutics stock opened at $0.01 on Friday. Pasithea Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.12. The stock has a 50-day moving average price of $0.01 and a 200 day moving average price of $0.02.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.